ClinicalTrials.gg
CompletedNCT01625234Updated Apr 30, 2026Results posted

Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer

A Phase 1/2 interventional study of Phase I: X-396 (ensartinib) and Phase II: X-396 (ensartinib) in Advanced Solid Tumors and Non-small Cell Lung Cancer, sponsored by Xcovery Holdings, Inc.. Completed at 14 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-30.

Sponsored by Xcovery Holdings, Inc. (part of Betta Pharmaceuticals Co., Ltd.) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
131
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 20 studies testing ensartinib in Carcinoma, Non-Small-Cell Lung — 9 open to participants now, 14 under way, 2 of them phase 3. ensartinib · Carcinoma, Non-Small-Cell Lung.

Enrollment
6th of 20
131 · median 48
Started
2012
the only one that year
Phase 1/2
3 of 20
1 open now
Registered
1st of 20
by date
Lead sponsor
2 of 20
Xcovery Holdings, Inc.

Among the 20 studies testing ensartinib in Carcinoma, Non-Small-Cell Lung, this one is the 6th largest by enrollment, is the only one that started in 2012, is one of 3 in phase 1/2, and was the 1st registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

9 of the 20 studies testing ensartinib in Carcinoma, Non-Small-Cell Lung are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About ensartinib

ensartinib: first FDA approval 2024 (ENSACOVE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing ensartinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This is the first human study to use X-396 (ensartinib), a drug being developed for treatment of advanced cancers. The initial purpose of the study is to determine the largest amount of X-396 that can be safely given to humans (the maximum tolerated dose). Once the recommended Phase 2 dose has been determined, an expansion phase will assess the preliminary anti-tumor activity of X-396 in ALK-positive non-small cell lung cancer. The study will also provide early information on how the body handles the drug (pharmacokinetics) and on the efficacy of X-396.

Read the detailed description

This is the first study of X-396 (ensartinib) in humans and the investigational drug will be given as a once or twice daily oral dose in 28 day cycles until there is disease progression or unacceptable safety issues. X-396 will be given to small groups of patients (1 - 6) at each dose level and the patients will be observed to see if there are any adverse safety effects. As long as there are no unacceptable safety issues after 28 days, the dose of X-396 will be increased for the next group of patients. This process will continue until the maximum tolerated dose (MTD) of X-396 is reached. Once the MTD is reached, up to 170 additional patients will also be given X-396 to further determine the activity of X-396 in patients with ALK-positive non-small cell lung cancer. These additional patients will be enrolled in the following expansion cohorts: ALK TKI-naïve patients, patients that progressed on crizotinib, patients that progressed on one or more 2nd generation ALK TKIs (patients may or may not have also received prior crizotinib), including patients with asymptomatic CNS metastases.

03

Conditions studied

  • Advanced Solid Tumors
  • Non-small Cell Lung Cancer

Keywords

  • Cancer
  • Tumors
  • ALK
  • NSCLC
  • Advanced Malignancies
  • Carcinoma, Non-Small-Cell Lung
  • Inflammatory Myofibroblastic Tumors
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. or cytologically confirmed diagnosis of advanced solid tumor . Patients may be ALK TKI-naive or may have received prior crizotinib and/or second generation ALK TKIs. In addition, patients with a known ALK 1198 mutation will be allowed.

    -For the expanded cohort portion of the study, patients must have NSCLC with ALK genomic alterations; however, patients will be allowed to enroll based on local FDA-approved ALK results.

  2. Eastern Cooperative Group ) Performance Status score of 0 or 1.
  3. Ability to swallow and retain oral medication.
  4. Adequate organ system function.
  5. Patients with treated or untreated asymptomatic may be allowed to enroll.
  6. Male patients willing to use adequate measures.
  7. Female patients who are not of , and female patients of child-bearing potential who agree to use adequate contraceptive measures.
  8. Patients must be ≥ 18 years of age.
  9. Patients must have measurable or evaluable disease for the dose escalation portion of the study and for the expanded cohort portion of the study (except for patients in the CNS metastases and cohorts).
  10. Willingness and ability to comply with the trial and follow-up procedures.
  11. Ability to understand the nature of this trial and give written .

Exclusion criteria

Exclusion Criteria:

  1. Patients currently receiving cancer therapy.
  2. Use of an drug within 21 days or 5 half-lives (whichever is shorter) prior to the first dose of X-396. A minimum of 10 days between treatment and X-396 and 2 days between ALK TKI and X-396.
  3. Any major surgery, radiotherapy, or immunotherapy within the last 21 days (focal radiation does not require a ; ≥4 weeks for WBRT). Chemotherapy regimens with delayed toxicity within the last 4 weeks. Chemotherapy regimens given continuously or on a weekly basis with limited potential for delayed toxicity within the last 2 weeks.
  4. Prior stem cell transplant.
  5. Patients with a known allergy or delayed reaction to drugs chemically related to X-396 (e.g., crizotinib) or to the active ingredient of X-396.
  6. Patients with primary CNS tumors are ineligible.
  7. Patients receiving substrates with narrow therapeutic indices, strong CYP3A inhibitors, and strong CYP3A inducers.
  8. Concomitant use of herbal medications at least 7 days prior to the first dose of study drug and throughout participation in the trial.
  9. Females who are pregnant or breastfeeding.
  10. Presence of active gastrointestinal (GI) disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of X-396.
  11. cardiovascular disease.
  12. Patients who are (including known infection), have a serious active infection at the time of treatment, have known , or have any serious underlying medical condition that would impair the ability of the patient to receive protocol treatment.
  13. Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol.
  14. Concurrent condition that in the investigator's opinion would jeopardize compliance with the protocol or would impart excessive risk associated with study participation that would make it inappropriate for the patient to be enrolled.
  15. Inability or unwillingness to comply with study and/or follow-up procedures outlined in the protocol.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
131 participants (actual)

Study arms

  • Experimental
    Phase I: X-396 (ensartinib)

    Dose escalation starting at 25 mg, oral once or twice a day, 28-day cycle. Number of Cycles: until progression or unacceptable toxicity develops

    Drug: Phase I: X-396 (ensartinib)

  • Experimental
    Phase II: X-396 (ensartinib)

    RP2D 225mg stratified based on prior treatment and CNS activity

    Drug: Phase II: X-396 (ensartinib)

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose

    To evaluate the safety/tolerability of X-396 (ensartinib) and determine the maximum tolerated dose (MTD) of X-396 as a single agent.

    Time frame: 28 Days

Secondary outcomes

  1. Number of Participants With Preliminary Tumor Response in ALK Positive Patients at 225 mg QD

    To explore the preliminary clinical tumor response after treatment with X-396 (ensartinib) given as a single agent in ALK positive patients at 225 mg QD. Subjects were assessed according to Response Evaluation Criteria in Solid Tumors version 1.1 criteria (and CNS lesions were also assessed by modified Response Assessment in Neuro-Oncology). Assessments by CT or MRI were performed after every even cycle of treatment. All assessments were to be performed within 7 days of the scheduled day of assessment. Tumor lesions followed on physical examination must have been assessed on Day 1 of each cycle and at the End-of-Study Treatment Visit.

    Time frame: 18 months

  2. Plasma Concentrations Cmax for Day 1

    To characterize the preliminary pharmacokinetics including Cmax f X-396 given as a single agent

    Time frame: 24 hours

  3. Plasma Tmax on Day 1

    To characterize the preliminary pharmacokinetics including T max of X-396 given as a single agent

    Time frame: 24 hours

  4. Plasma Concentrations AUC on Day 1

    To characterize the preliminary pharmacokinetics including AUC of X-396 given as a single agent

    Time frame: 0, 0.5h, 1.0h , 2.0 h, 4.0h, 6.0h, 8.0h, 24.0h,

  5. Plasma Concentrations Half-life on Day 1

    To characterize the preliminary pharmacokinetics including half life of X-396 given as a single agent

    Time frame: 24 hours

07

Results

Posted Apr 30, 2026

Participant flow

A total of 131 subjects were treated at 16 sites in the US, including 37 subjects in the escalation cohorts and 94 subjects in the expansion cohort.

Participant flow — Overall Study
MilestonePhase I: X-396 (Ensartinib) at 25 mgPhase I: X-396 (Ensartinib) at 50 mgPhase I: X-396 (Ensartinib) at 100 mgPhase I: X-396 (Ensartinib) at 200 mgPhase I: X-396 (Ensartinib) at 225 mgPhase I: X-396 (Ensartinib) at 250 mgPhase II: X-396 (Ensartinib) at 225 mg
Started4351141094
Completed4351141094
Not completed0000000

Outcome measures

PrimaryMaximum Tolerated Dose

To evaluate the safety/tolerability of X-396 (ensartinib) and determine the maximum tolerated dose (MTD) of X-396 as a single agent.

Time frame:
28 Days
Reported as:
Number · mg
Maximum Tolerated Dose
mgPhase I/II X:396 Ensartinib
Maximum Tolerated Dose250
SecondaryNumber of Participants With Preliminary Tumor Response in ALK Positive Patients at 225 mg QD

To explore the preliminary clinical tumor response after treatment with X-396 (ensartinib) given as a single agent in ALK positive patients at 225 mg QD. Subjects were assessed according to Response Evaluation Criteria in Solid Tumors version 1.1 criteria (and CNS lesions were also assessed by modified Response Assessment in Neuro-Oncology). Assessments by CT or MRI were performed after every even cycle of treatment. All assessments were to be performed within 7 days of the scheduled day of assessment. Tumor lesions followed on physical examination must have been assessed on Day 1 of each cycle and at the End-of-Study Treatment Visit.

Time frame:
18 months
Reported as:
Number · participants
Number of Participants With Preliminary Tumor Response in ALK Positive Patients at 225 mg QD
participantsX-396 (Ensartinib) 225 mg
Number of Participants With Preliminary Tumor Response in ALK Positive Patients at 225 mg QD34 (31.1 to 53.5)
SecondaryPlasma Concentrations Cmax for Day 1

To characterize the preliminary pharmacokinetics including Cmax f X-396 given as a single agent

Time frame:
24 hours
Reported as:
Geometric mean · ng/ml
Plasma Concentrations Cmax for Day 1
ng/mlPhase I: X-396 (Ensartinib) at 25mgPhase II: X-396 (Ensartinib) at 225 mg (Fasted)Phase I: X-396 (Ensartinib) at 50 mgPhase I: X-396 (Ensartinib) at 100 mgPhase I: X-396 (Ensartinib) at 200 mg (Fasted)Phase I: X-396 (Ensartinib) at 250mgPhase I: X-396 (Ensartinib) at 225mgPhase II: X-396 (Ensartinib) at 225 mg (Fed)Phase I: X-396 (Ensartinib) at 200 mg (Fed)
Plasma Concentrations Cmax for Day 15 ± 81.9136 ± 40.029 ± 86.553 ± 57.7114 ± 79.8182 ± 44.494 ± 44.0125 ± 52.7109 ± 44.5
SecondaryPlasma Tmax on Day 1

To characterize the preliminary pharmacokinetics including T max of X-396 given as a single agent

Time frame:
24 hours
Reported as:
Median · hour
Plasma Tmax on Day 1
hourPhase I: X-396 (Ensartinib) at 25mgPhase II: X-396 (Ensartinib) at 225 mg (Fasted)Phase I: X-396 (Ensartinib) at 50 mgPhase I: X-396 (Ensartinib) at 100 mgPhase I: X-396 (Ensartinib) at 200 mg (Fasted)Phase I: X-396 (Ensartinib) at 250mgPhase I: X-396 (Ensartinib) at 225mgPhase II: X-396 (Ensartinib) at 225 mg (Fed)Phase I: X-396 (Ensartinib) at 200 mg (Fed)
Plasma Tmax on Day 13.2 (2.25 to 6.00)3.2 (1.08 to 23.8)2.0 (1.00 to 6.00)3.0 (2.98 to 8.20)3.5 (2.03 to 8.23)3.1 (1.00 to 7.17)6.0 (2.37 to 8.00)4.0 (1.03 to 24.0)4.0 (3.00 to 6.00)
SecondaryPlasma Concentrations AUC on Day 1

To characterize the preliminary pharmacokinetics including AUC of X-396 given as a single agent

Time frame:
0, 0.5h, 1.0h , 2.0 h, 4.0h, 6.0h, 8.0h, 24.0h,
Reported as:
Geometric mean · h·ng/mL
Plasma Concentrations AUC on Day 1
h·ng/mLPhase I: X-396 (Ensartinib) at 25mgPhase II: X-396 (Ensartinib) at 225 mg (Fasted)Phase I: X-396 (Ensartinib) at 50 mgPhase I: X-396 (Ensartinib) at 100 mgPhase I: X-396 (Ensartinib) at 200 mg (Fasted)Phase I: X-396 (Ensartinib) at 250mgPhase I: X-396 (Ensartinib) at 225mgPhase II: X-396 (Ensartinib) at 225 mg (Fed)Phase I: X-396 (Ensartinib) at 200 mg (Fed)
Plasma Concentrations AUC on Day 131 ± 39.0756 ± 43.3134 ± 71.2250 ± 84.1614 ± 66.8973 ± 42.6394 ± 74.9664 ± 66.3513 ± 28.3
SecondaryPlasma Concentrations Half-life on Day 1

To characterize the preliminary pharmacokinetics including half life of X-396 given as a single agent

Time frame:
24 hours
Reported as:
Geometric mean · hour
Plasma Concentrations Half-life on Day 1
hourPhase I: X-396 (Ensartinib) at 25mgPhase II: X-396 (Ensartinib) at 225 mg (Fasted)Phase I: X-396 (Ensartinib) at 50 mgPhase I: X-396 (Ensartinib) at 100 mgPhase I: X-396 (Ensartinib) at 200 mg (Fasted)Phase I: X-396 (Ensartinib) at 250mgPhase I: X-396 (Ensartinib) at 225mgPhase II: X-396 (Ensartinib) at 225 mg (Fed)Phase I: X-396 (Ensartinib) at 200 mg (Fed)
Plasma Concentrations Half-life on Day 10 ± 018 ± 52.10 ± 012 ± 17.518 ± 20.123 ± 55.20 ± 014 ± 9.180 ± 0

Adverse events

Collected over From first dose up to 30 days after the last dose of Ensartinib (up to 228 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase I: X-396 (Ensartinib) at 25 mg0/4 (0%)1/4 (25%)3/4 (75%)
Phase I: X-396 (Ensartinib) at 50 mg0/3 (0%)1/3 (33.3%)3/3 (100%)
Phase I: X-396 (Ensartinib) at 100 mg1/5 (20%)2/5 (40%)4/5 (80%)
Phase I: X-396 (Ensartinib) at 200 mg1/11 (9.1%)6/11 (54.5%)9/11 (81.8%)
Phase I: X-396 (Ensartinib) at 225 mg0/4 (0%)2/4 (50%)2/4 (50%)
Phase I: X-396 (Ensartinib) at 250 mg0/10 (0%)5/10 (50%)9/10 (90%)
Phase II: X-396 (Ensartinib) at 225 mg3/94 (3.2%)41/94 (43.6%)84/94 (89.4%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventPhase I: X-396 (Ensartinib) at 25 mgPhase I: X-396 (Ensartinib) at 50 mgPhase I: X-396 (Ensartinib) at 100 mgPhase I: X-396 (Ensartinib) at 200 mgPhase I: X-396 (Ensartinib) at 225 mgPhase I: X-396 (Ensartinib) at 250 mgPhase II: X-396 (Ensartinib) at 225 mg
CellulitisInfections and infestations0/41/30/52/110/40/101/94
Metabolism and connective tissue disordersMetabolism and nutrition disorders0/41/30/53/110/40/103/94
Nervous system disordersNervous system disorders0/41/30/50/111/41/109/94
Infections and infestationsInfections and infestations0/41/31/53/110/41/1012/94
Blood and lymphatic systemBlood and lymphatic system disorders1/40/30/50/110/40/103/94
ConvulsionNervous system disorders0/40/30/50/111/41/103/94
PneumoniaInfections and infestations0/40/31/52/110/40/104/94
Cardiac disordersCardiac disorders0/40/30/51/110/41/107/94
Muscoskeletal and connective tissue disordersMusculoskeletal and connective tissue disorders0/40/30/51/110/41/102/94
Muscular weaknessMusculoskeletal and connective tissue disorders0/40/30/50/110/41/101/94
Most frequent other events
Most frequent other events
EventPhase I: X-396 (Ensartinib) at 25 mgPhase I: X-396 (Ensartinib) at 50 mgPhase I: X-396 (Ensartinib) at 100 mgPhase I: X-396 (Ensartinib) at 200 mgPhase I: X-396 (Ensartinib) at 225 mgPhase I: X-396 (Ensartinib) at 250 mgPhase II: X-396 (Ensartinib) at 225 mg
Gastrointestinal disordersGastrointestinal disorders0/41/32/56/111/45/1057/94
VomitingGastrointestinal disorders0/41/30/54/111/45/1024/94
NauseaGastrointestinal disorders0/41/31/55/111/43/1036/94
Blood and lymphaticBlood and lymphatic system disorders1/40/31/50/110/40/1011/94
AnaemiaBlood and lymphatic system disorders1/40/31/50/110/40/108/94
Blood Creatinine increasedInvestigations1/40/30/50/110/40/109/94

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Phase I: X-396 (Ensartinib) 25 mgPhase I: X-396 (Ensartinib) 50 mgPhase I: X-396 (Ensartinib) 100 mgPhase I: X-396 (Ensartinib) 200 mgPhase I: X-396 (Ensartinib) 225 mgPhase I: X-396 (Ensartinib) 250 mgPhase II: X-396 (Ensartinib) 225 mgTotal
<=18 years00000000
Between 18 and 65 years4351141094131
>=65 years00000000
Age, Continuous
Age, Continuous(Years)Phase I: X-396 (Ensartinib) 25 mgPhase I: X-396 (Ensartinib) 50 mgPhase I: X-396 (Ensartinib) 100 mgPhase I: X-396 (Ensartinib) 200 mgPhase I: X-396 (Ensartinib) 225 mgPhase I: X-396 (Ensartinib) 250 mgPhase II: X-396 (Ensartinib) 225 mgTotal
Mean53.5 ± 7.3357.7 ± 16.2056.2 ± 4.8757.5 ± 14.0560.0 ± 12.2555.4 ± 11.5856.0 ± 13.5956.2 ± 12.92
Sex: Female, Male
Sex: Female, Male(Participants)Phase I: X-396 (Ensartinib) 25 mgPhase I: X-396 (Ensartinib) 50 mgPhase I: X-396 (Ensartinib) 100 mgPhase I: X-396 (Ensartinib) 200 mgPhase I: X-396 (Ensartinib) 225 mgPhase I: X-396 (Ensartinib) 250 mgPhase II: X-396 (Ensartinib) 225 mgTotal
Female2125264664
Male2236244867
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Phase I: X-396 (Ensartinib) 25 mgPhase I: X-396 (Ensartinib) 50 mgPhase I: X-396 (Ensartinib) 100 mgPhase I: X-396 (Ensartinib) 200 mgPhase I: X-396 (Ensartinib) 225 mgPhase I: X-396 (Ensartinib) 250 mgPhase II: X-396 (Ensartinib) 225 mgTotal
American Indian or Alaska Native00000022
Asian0001001819
Native Hawaiian or Other Pacific Islander00000000
Black or African American11100047
White324104106598
More than one race00000011
Unknown or Not Reported00000044
Region of Enrollment
Region of Enrollment(participants)Phase I: X-396 (Ensartinib) 25 mgPhase I: X-396 (Ensartinib) 50 mgPhase I: X-396 (Ensartinib) 100 mgPhase I: X-396 (Ensartinib) 200 mgPhase I: X-396 (Ensartinib) 225 mgPhase I: X-396 (Ensartinib) 250 mgPhase II: X-396 (Ensartinib) 225 mgTotal
United States4351141094131
ECOG Performance Status
ECOG Performance Status(# of patients with Score Grade (0-5))Phase I: X-396 (Ensartinib) 25 mgPhase I: X-396 (Ensartinib) 50 mgPhase I: X-396 (Ensartinib) 100 mgPhase I: X-396 (Ensartinib) 200 mgPhase I: X-396 (Ensartinib) 225 mgPhase I: X-396 (Ensartinib) 250 mgPhase II: X-396 (Ensartinib) 225 mgTotal
01036242945
13325266384
200000011
Not Determined00000011
Tobacco user
Tobacco user(Participants)Phase I: X-396 (Ensartinib) 25 mgPhase I: X-396 (Ensartinib) 50 mgPhase I: X-396 (Ensartinib) 100 mgPhase I: X-396 (Ensartinib) 200 mgPhase I: X-396 (Ensartinib) 225 mgPhase I: X-396 (Ensartinib) 250 mgPhase II: X-396 (Ensartinib) 225 mgTotal
Never2125385778
Former2215123649
Current00210014
08

Study locations

14 sites
  • City of Hope National Med Ctr
    Duarte, California 91010, United States
  • UCSD Moores Cancer Center
    La Jolla, California 92093, United States
  • University of Southern California Norris Comprehensive Cancer Center
    Los Angeles, California 90033, United States
  • Stanford University
    Stanford, California 94305, United States
  • Moffitt Cancer Center
    Tampa, Florida 33612, United States
  • Walter Reed National Military Medical Center
    Bethesda, Maryland 20889, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
  • New York University Langone Medical Center
    New York, New York 10016, United States
  • Providence Portland Medical Center
    Portland, Oregon 97213, United States
  • Tennessee Oncology, PLLC
    Nashville, Tennessee 37203, United States
  • Vanderbilt University
    Nashville, Tennessee 37240, United States
  • University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • University of Wisconsin Carbone Cancer Ctr
    Madison, Wisconsin 53792, United States
09

References and documents

Publications

  • Lovly CM, Heuckmann JM, de Stanchina E, Chen H, Thomas RK, Liang C, Pao W. Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors. Cancer Res. 2011 Jul 15;71(14):4920-31. doi: 10.1158/0008-5472.CAN-10-3879. Epub 2011 May 25. PubMed 21613408 ↗
  • Horn L, Infante JR, Reckamp KL, Blumenschein GR, Leal TA, Waqar SN, Gitlitz BJ, Sanborn RE, Whisenant JG, Du L, Neal JW, Gockerman JP, Dukart G, Harrow K, Liang C, Gibbons JJ, Holzhausen A, Lovly CM, Wakelee HA. Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study. Clin Cancer Res. 2018 Jun 15;24(12):2771-2779. doi: 10.1158/1078-0432.CCR-17-2398. Epub 2018 Mar 21. PubMed 29563138 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2012, a primary completion of Sep 2020 and a completion of Sep 2020. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2026, 5 years 7 months after primary completion. A results delay was requested in Sep 2021.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2012
First posted
Jun 21, 2012
Start
Jun 2012
Primary completionActual
Sep 17, 2020
CompletionActual
Sep 17, 2020
Results delay requested
Sep 13, 2021
Results first posted
Apr 30, 2026
Last update
Apr 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01625234
Responsible party
Sponsor
First posted
Jun 21, 2012
Start date
Jun 2012
Primary completion
Sep 17, 2020
Completion
Sep 17, 2020
Results posted
Apr 30, 2026
Last update
Apr 30, 2026

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ensartinib

Start the discussion